Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference
May 18 2022 - 7:30AM
Business Wire
Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage
regenerative medicine company focused on developing therapeutics to
activate a person’s innate regenerative potential to restore
function, today announced that Chief Scientific Officer Dr.
Christopher Loose will present at the upcoming H.C. Wainwright
Global Investment Conference.
Dr. Loose’s presentation will be available to view beginning at
7:00 a.m. ET on May 24th and may be accessed on the investors
section of Frequency’s website, investors.frequencytx.com.
About Frequency Therapeutics
Frequency Therapeutics is leading a new category in regenerative
medicine that aims to restore function – first in hearing loss and
then in multiple sclerosis (MS) – by developing therapeutics that
activate a person’s innate regenerative potential within the body
through the activation of progenitor cells to restore lost
function. Frequency’s hearing research focuses on cochlear
restoration and auditory repair, and its lead asset, FX-322, is a
small-molecule product candidate that is the first to show
statistically significant and clinically meaningful hearing
improvements in clinical trials for SNHL. Frequency is also
following early restorative signals in MS to develop medicines with
the same underlying regenerative science being brought to hearing
loss.
Headquartered in Lexington, Mass., Frequency has an ex-U.S.
license and collaboration agreement with Astellas Pharma Inc. for
FX-322, as well as additional collaboration and licensing
agreements with academic and nonprofit research organizations
including Massachusetts Eye and Ear, Mass General Brigham, the
Massachusetts Institute of Technology, the Scripps Research
Institute and Cambridge Enterprises Limited. For more information,
visit www.frequencytx.com and follow Frequency on Twitter
@Frequencytx.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220518005346/en/
Investor Contact: Carlo Tanzi, Ph.D. Kendall Investor
Relations ctanzi@kendallir.com 617-914-0008
Media Contact: Suzanne Day Frequency Therapeutics
sday@frequencytx.com 781-496-2211
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Aug 2024 to Sep 2024
Frequency Therapeutics (NASDAQ:FREQ)
Historical Stock Chart
From Sep 2023 to Sep 2024